Piramal Pharma Q2 Results 2025 Highlights: Net Profit Falls 539.22% & Revenue Down 8.83% YoY

Piramal Pharma Q2 Results FY26: During Q2 FY26, Piramal Pharma’s profit decreased 539.22% YoY, while revenue decreased by 8.83% YoY. The company posted robust numbers, with Q2 PAT at ₹-99.2 Crores and revenue at ₹2,043.72 crores. Piramal Pharma announced its Q2 results on 5th November 2025.  

Piramal Pharma Q2 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

(Figures in crores)

Piramal Pharma Products Q2 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

(Figures in crores)

Piramal Pharma Products Q2 Results FY26 Highlights (Q2 FY26 vs FY25)

• Piramal Pharma clocked Q2 FY26 consolidated revenue of ₹2,043.72 crores vs ₹2,241.75 crores. 
• On the profit front, Piramal Pharma earned a consolidated PAT of ₹-99.2 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹22.59 crore.
• According to the consolidated figures, Piramal Pharma’s quarterly PAT decreased by 539.22% YoY, while revenue decreased by -8.83%.
• Piramal Pharma clocked Q2 FY26 standalone revenue of ₹1,127.26 crores vs ₹1,284.39 Crores. 
• On the profit front, Piramal Pharma earned a standalone PAT of ₹196.33 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹210.06 crore.
• According to the standalone figures, Piramal Pharma’s quarterly PAT decreased by -6.54% YoY, while revenue decreased by -12.23%.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Piramal Pharma Share Price Performance

On the opening bell on 7th November 2025, Piramal Pharma shares opened at ₹198.70 per share. However, the initial gains have since eroded, and Piramal Pharma’s shares are currently trading at ₹199.50 per share, which is lower than the opening price.    

Considering the long-term achievements, Piramal Pharma’s shares have yielded returns of approximately -6.77% over the past six months, and one-year returns stand at -31.85%. Over the maximum timeframe, Piramal Pharma shares delivered an 18.93% return to investors. 

What Analysts Expect Post Q2 Results?

Following Piramal Pharma’s robust Q2 results, analysts expect its share price to rise. According to analysts, Piramal Pharma’s share price is expected to reach ₹200.00 per share in the coming year; however, in a downturn, it could fall to ₹160.60 per share. However, one must ignore stock market volatility and invest in Piramal Pharma’s shares after thorough research. 

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Nestle Q2 Results FY26: Q2 PAT Falls 17.38% to ₹743.17 Crore; Revenue Up 10.57% YoY

Inspira Enterprise India IPO Details: Everything You Should Know about 

Swaraj Engines Q2 Results FY26: Q2 PAT Rises 8.88% to ₹49 Crore; Revenue Up 8.62% YoY

HDB Financial Q2 Results FY26: Q2 PAT Falls 1.5% to ₹581 Crore; Revenue Up 13.42% YoY

BEL Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Paytm Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Blue Dart Gears Up for Q2 Reveal on 28th October; Check Key Expectations Here